Epilepsy Market in the US 2015-2019

Epilepsy Market in the US 2015-2019

Category : Pharmaceuticals
Published On : January  2015
Pages : 64



TOLL FREE
+1-971-202-1575
------------ Or -------------
help@researchbeam.com
About Epilepsy
Epilepsy is a spectrum of brain disorders varying from benign to severe, disabling, and life-threatening symptoms. It is caused by various factors ranging from brain malformations and tumors to meningitis, high-risk pregnancies, and birth trauma. However, when the underlying cause of the disease is unidentified, as in the majority of the cases, it is known as idiopathic epilepsy. Epilepsy is characterized by repeated occurrence of generalized or focal seizures. An imbalance between the inhibitory and excitatory signals of the brain, leading to a sudden onset of excitation, results in seizures. Occurrence of two or more unprovoked seizures is an important criterion to diagnose a person as being epileptic. 
TechNavio's analysts forecast the Epilepsy market in the US to grow at a CAGR of 4.85 percent over the period 2014-2019.
Covered in this Report
The Epilepsy market in the US can be divided into three segments: First-generation Drugs, Second-generation Drugs, and Third-generation Drugs. This report covers the present scenario and the growth prospects of the Epilepsy market in the US for the period 2015-2019. To calculate the market size, the report considers the revenue generated through the sales of anti-epileptic drugs approved in the US to treat the symptoms of epilepsy. 
TechNavio's report, Epilepsy Market in the US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the landscape of the Epilepsy Market in the US and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Vendors
• GlaxoSmithKline 
• Pfizer 
• UCB  
Market Driver
• Unmet Medical Needs
• For a full, detailed list, view our report
Market Challenge
• Generic Erosion
• For a full, detailed list, view our report
Market Trend
• Reformulation of Marketed Drugs
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
03.2.1 Product Profiles
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Disease Overview
05.1 Epilepsy
05.1.1 Etiology
05.1.2 Signs and Symptoms
05.1.3 Diagnosis
05.1.4 Epidemiology
06. Introduction
07. Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.3 Five Forces Analysis
08. Market Segmentation by Generation of Drugs
09. Buying Criteria
10. Market Growth Drivers
11. Drivers and their Impact
12. Market Challenges
13. Impact of Drivers and Challenges
14. Market Trends
15. Trends and their Impact
16. Vendor Landscape
16.1 Competitive Scenario
16.1.1 Key News
16.1.2 Mergers and Acquisitions
16.2 Market Share Analysis 2014
16.2.1 GlaxoSmithKline
16.2.2 UCB
16.2.3 Pfizer
16.3 Other Prominent Vendors
17. Key Vendor Analysis
17.1 GlaxoSmithKline
17.1.1 Key Facts
17.1.2 Business Overview
17.1.3 Business Segmentation
17.1.4 Business Segmentation by Revenue 2012 and 2013
17.1.5 Sales by Geography
17.1.6 Pipeline Products
17.1.7 Business Strategy
17.1.8 Key Information
17.1.9 SWOT Analysis
17.2 Pfizer
17.2.1 Key Facts
17.2.2 Business Overview
17.2.3 Business Segmentation by Revenue 2013
17.2.4 Business Segmentation by Revenue 2012 and 2013
17.2.5 Geographical Segmentation by Revenue
17.2.6 Business Strategy
17.2.7 Key Developments
17.2.8 SWOT Analysis
17.3 UCB
17.3.1 Key Facts
17.3.2 Business Overview
17.3.3 Product Segmentation by Revenue 2013
17.3.4 Product Segmentation by Revenue 2012 and 2013
17.3.5 Geographical Segmentation by Revenue 2013
17.3.6 Business Strategy
17.3.7 Recent Developments
17.3.8 SWOT Analysis
18. Other Reports in this Series

List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Epilepsy Market in the US 2014-2019 (US$ million)
Exhibit 3: Epilepsy Market in the US Segmentation by Generation of Drugs
Exhibit 4: Prevalence of Active Epilepsy per 1,000 by age in US
Exhibit 5: Lamictal Revenue 2011-2013 in the US (US$ million)
Exhibit 6: Lamictal Sales Segmentation by Geography 2013
Exhibit 7: Vimpat Revenue 2011-2013 in the US (US$ million)
Exhibit 8: Vimpat Sales Segmentation by Geography 2013
Exhibit 9: Keppra Sales Segmentation by Geography 2013
Exhibit 10: Keppra Revenue 2010-2013 in the US (US$ million)
Exhibit 11: Lyrica Revenue 2011-2013 in the US (US$ million)
Exhibit 12: GlaxoSmithKline: Business Segmentation 2013
Exhibit 13: GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 14: GlaxoSmithKline: Sales by Geography 2013
Exhibit 15: GlaxoSmithKline: Pipeline Products 2013
Exhibit 16: Pfizer: Business Segmentation by Revenue 2013
Exhibit 17: Pfizer: Business Segmentation by Revenue 2012 and 2013
Exhibit 18: Pfizer: Geographical Segmentation by Revenue 2013
Exhibit 19: UCB: Product Segmentation by Revenue 2013
Exhibit 20: UCB: Product Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 21: UCB: Geographical Segmentation by Revenue 2013

Enquiry Before Buy
image
Can´t read the image ? refresh here.